The researchers employed a descriptive analysis of current clinicobiologic patterns and current diagnosis choices in chronic myeloid leukaemia (CML), as well as an updated identification of management techniques and therapy strategies in this chronic myeloproliferative neoplasm. CML is a clonal hematopoietic malignancy that arises from the malignant transformation of a pluripotent stem cell while retaining the ability to differentiate into all cell types. Donor lymphocyte infusions, which are still employed, typically in conjunction with tyrosine kinase inhibitors (TKIs), in patients with relapses after allogeneic hematopoietic stem cell transplantation, are examples of therapeutic techniques that support established immunological treatments (HSCT). TKI-targeted therapy remains the treatment of choice for CML patients of any age, and may be preceded by other therapies.
Author(s) Details
Vasile Musteata
Discipline of Hematology, State University of Medicine and Pharmacy Nicolae Testemitanu, Chisinau, Republic of Moldova and Department of Hematology, Institute of Oncology, Chisinau, Republic of Moldova.
View Book:- https://stm.bookpi.org/IBDMCML/article/view/6918
No comments:
Post a Comment